Onxeo (EU: ONXEO)

Last close As at 05/08/2026

0.00 (0.00%)

Market capitalisation

Latest Insights

View More

Healthcare | edison tv

Onxeo – Edison Open House interview

Healthcare | edison tv

Onxeo – executive interview

Healthcare | Update

Onxeo — Progress with both REVOCAN and DRIIV-1b trials

Healthcare | Update

Onxeo — Expanding AsiDNA R&D programme

Market Data

Share Price
Market Cap
52-Week High
52-Week Low
% Change 1M
% Change 6M
% Change 12M
Ave. Daily Volume 1yr

Sector

Healthcare

Research

Update

Healthcare

Onxeo — Expanding AsiDNA R&D programme

Flash note

Healthcare

Onxeo — First Phase Ib DRIIV results released

Outlook

Healthcare

Onxeo — Next generation of DNA damage repair inhibitors

Outlook

Healthcare

Onxeo — Introducing platON; AsiDNA approaches Phase I

Flash note

Healthcare

Onxeo — First significant milestone with AsiDNA achieved

Further insights

insight

Healthcare

DNA damage repair inhibitors

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.